AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; offers specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets, as well as provides demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was founded in 1985 and is headquartered in Conshohocken, Pennsylvania.
IPO Year:
Exchange: NYSE
Website: amerisourcebergen.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/31/2023 | $185.00 | Buy | Citigroup |
| 1/31/2023 | $185.00 | Outperform | Evercore ISI |
| 10/11/2022 | $160.00 → $169.00 | Neutral → Buy | BofA Securities |
| 8/22/2022 | Equal-Weight | Morgan Stanley | |
| 7/11/2022 | $150.00 | Outperform → In-line | Evercore ISI |
| 6/7/2022 | $167.00 → $178.00 | Hold → Buy | Deutsche Bank |
| 5/26/2022 | Equal Weight → Overweight | Barclays | |
| 4/12/2022 | $178.00 | Overweight → Equal-Weight | Morgan Stanley |
| 4/1/2022 | $180.00 | Outperform | Credit Suisse |
| 2/3/2022 | $130.00 → $139.00 | Neutral | Mizuho |
SC 13G - Cencora, Inc. (0001140859) (Subject)
SC 13G/A - Cencora, Inc. (0001140859) (Subject)
SC 13G/A - AMERISOURCEBERGEN CORP (0001140859) (Subject)
SC 13G/A - AMERISOURCEBERGEN CORP (0001140859) (Subject)
SC 13G/A - AMERISOURCEBERGEN CORP (0001140859) (Subject)
VALLEY FORGE, Pa.--(BUSINESS WIRE)--AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors declared a quarterly dividend of $0.44 per common share, payable March 1, 2021, to stockholders of record at the close of business on February 12, 2021. About AmerisourceBergen AmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care. Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the pharmaceutical supply chain. Global manufacturers depend on us for services that drive commercial success for their products. Through our dail
Citigroup initiated coverage of AmerisourceBergen with a rating of Buy and set a new price target of $185.00
Evercore ISI resumed coverage of AmerisourceBergen with a rating of Outperform and set a new price target of $185.00
BofA Securities upgraded AmerisourceBergen from Neutral to Buy and set a new price target of $169.00 from $160.00 previously
Morgan Stanley resumed coverage of AmerisourceBergen with a rating of Equal-Weight
Evercore ISI downgraded AmerisourceBergen from Outperform to In-line and set a new price target of $150.00
Deutsche Bank upgraded AmerisourceBergen from Hold to Buy and set a new price target of $178.00 from $167.00 previously
Barclays upgraded AmerisourceBergen from Equal Weight to Overweight
Morgan Stanley downgraded AmerisourceBergen from Overweight to Equal-Weight and set a new price target of $178.00
Credit Suisse resumed coverage of AmerisourceBergen with a rating of Outperform and set a new price target of $180.00
Mizuho reiterated coverage of AmerisourceBergen with a rating of Neutral and set a new price target of $139.00 from $130.00 previously
8-K - Cencora, Inc. (0001140859) (Filer)
8-K - Cencora, Inc. (0001140859) (Filer)
FWP - Cencora, Inc. (0001140859) (Subject)
424B5 - Cencora, Inc. (0001140859) (Filer)
10-Q - Cencora, Inc. (0001140859) (Filer)
8-K - Cencora, Inc. (0001140859) (Filer)
ARS - Cencora, Inc. (0001140859) (Filer)
DEFA14A - Cencora, Inc. (0001140859) (Filer)
DEF 14A - Cencora, Inc. (0001140859) (Filer)
PRE 14A - Cencora, Inc. (0001140859) (Filer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
Revenue of $66.9 billion for the Third Quarter, an 11.5 Percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $2.35 and Adjusted Diluted EPS of $2.92 Adjusted Diluted EPS Guidance Range Raised to $11.85 to $11.95 for Fiscal 2023 Company will begin operating as Cencora and trading under the ticker symbol "COR," effective August 30, 2023 AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2023 third quarter ended June 30, 2023, revenue increased 11.5 percent year-over-year to $66.9 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compare
AmerisourceBergen Corporation (NYSE:ABC) today announced that it plans to release its results for the Third Quarter of Fiscal 2023 on Wednesday, August 2, 2023, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 2, 2023. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.amerisourcebergen.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled st
Revenue of $63.5 billion for the Second Quarter, a 9.9 Percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $2.13 and Adjusted Diluted EPS of $3.50 Adjusted Diluted EPS Guidance Range Raised to $11.70 to $11.90 for Fiscal 2023 AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2023 second quarter ended March 31, 2023, revenue increased 9.9 percent year-over-year to $63.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to $2.59 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that
AmerisourceBergen Corporation (NYSE:ABC) today announced that it plans to release its results for the Second Quarter of Fiscal 2023 on Tuesday, May 2, 2023, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 2, 2023. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.amerisourcebergen.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time o
Revenues of $62.8 billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year First Quarter GAAP Diluted EPS of $2.33 and Adjusted Diluted EPS of $2.71 Adjusted Diluted EPS Guidance Range Raised to $11.50 to $11.75 for Fiscal 2023 AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2023 first quarter ended December 31, 2022, revenue increased 5.4 percent year-over-year to $62.8 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to $2.13 in the prior year first quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that exclu
AmerisourceBergen Corporation (NYSE:ABC) today announced that it plans to release its results for the First Quarter of Fiscal 2023 on Wednesday, February 1, 2023, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 1, 2023. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.amerisourcebergen.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled s
Transaction Highlights Walgreens Boots Alliance announces the sale of shares of AmerisourceBergen Corporation for proceeds of approximately $1.0 billion Approximately $0.8 billion sold pursuant to Rule 144 along with a concurrent share repurchase by AmerisourceBergen of approximately $0.2 billion Proceeds to Walgreens Boots Alliance will be used primarily for debt paydown and the funding of the company's strategic priorities, including the definitive agreement for VillageMD to acquire Summit Health-CityMD No change to ongoing collaboration and long-term strategic partnership Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced that it has sold shares of AmerisourceBergen Co
Revenue of $61.2 Billion for the Fourth Quarter, a 3.8 Percent Year-Over-Year Increase Fourth Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.60 Revenue of $238.6 Billion for Fiscal Year 2022, an 11.5 Percent Year-Over-Year Increase Fiscal Year 2022 GAAP Diluted EPS of $8.04 and Adjusted Diluted EPS of $11.03 AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2022 fourth quarter ended September 30, 2022, revenue increased 3.8 percent to $61.2 billion. Revenue increased 11.5 percent to $238.6 billion for the fiscal year. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.40 for the Septe
AmerisourceBergen Corporation (NYSE:ABC) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2022 on Thursday, November 3, 2022, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 3, 2022. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.amerisourcebergen.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled s
Revenues of $60.1 billion for the Third Quarter, a 12.5 Percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $1.92 and Adjusted Diluted EPS of $2.62 Adjusted Diluted EPS Guidance Range Raised to $10.90 to $11.10 for Fiscal 2022 AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2022 third quarter ended June 30, 2022, revenue increased 12.5 percent year-over-year to $60.1 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.92 for the June quarter of fiscal 2022 compared to $1.40 in the prior year quarter. Adjusted diluted EPS, which is a non-GAAP measure that excludes items described
AmerisourceBergen Corporation (NYSE:ABC) today announced that its Board of Directors has elected Werner Baumann and Lauren M. Tyler as new independent directors, effective October 1, 2023. With the election of Mr. Baumann and Ms. Tyler, the Board of Directors will increase from ten to twelve members, ten of whom are independent. "We look forward to welcoming Mr. Baumann and Ms. Tyler to AmerisourceBergen's Board of Directors. Their experience at preeminent multinational companies and unique perspectives will complement our Board's skill sets and help oversee the company's long-term, sustainable growth," said Mark Durcan, Lead Independent Director. "Werner and Lauren's expertise in their
Transaction Highlights Walgreens Boots Alliance announces the sale of shares of AmerisourceBergen Corporation pursuant to prepaid variable share forward transactions executed through a registered public offering for current proceeds of approximately $1.6 billion and, depending on the stock price at the time, potentially additional proceeds at maturity, along with a concurrent share repurchase by AmerisourceBergen of approximately $250 million Prepaid variable share forward transactions provide liquidity while maintaining ability to participate in potential stock price appreciation Proceeds to Walgreens Boots Alliance will be used primarily for debt paydown and general corporate pur
AmerisourceBergen Corporation (NYSE:ABC) (the "Company") announced today a registered public offering of 10.5 million shares of common stock of the Company in connection with Walgreens Boots Alliance Holdings LLC (the "Selling Stockholder") entering into prepaid variable share forward transactions (the "variable forward transactions") relating to the Company's common stock with certain counterparties (the "counterparties"). The Company has been advised that, in order to establish their initial hedge positions with respect to the variable forward transactions, the counterparties or their affiliates will borrow an aggregate of 7,293,548 shares of the Company's common stock from third-party
Revenue of $66.9 billion for the Third Quarter, an 11.5 Percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $2.35 and Adjusted Diluted EPS of $2.92 Adjusted Diluted EPS Guidance Range Raised to $11.85 to $11.95 for Fiscal 2023 Company will begin operating as Cencora and trading under the ticker symbol "COR," effective August 30, 2023 AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2023 third quarter ended June 30, 2023, revenue increased 11.5 percent year-over-year to $66.9 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compare
AmerisourceBergen Corporation (NYSE:ABC) today announced that it plans to release its results for the Third Quarter of Fiscal 2023 on Wednesday, August 2, 2023, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 2, 2023. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.amerisourcebergen.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled st
TPG (NASDAQ:TPG), a global alternative asset management firm, and AmerisourceBergen Corporation (NYSE:ABC) today announced the completion of their previously announced acquisition of OneOncology, a network of leading oncology practices. TPG has acquired a majority interest in OneOncology, and AmerisourceBergen has acquired a minority interest in the company. OneOncology's affiliated practices, physicians, and management team have also retained a minority interest in the company. The partnership provides OneOncology with additional resources to grow its platform and invest behind clinical, operational, and technical capabilities to continue to deliver high-quality, comprehensive patient ca
AmerisourceBergen Corporation (NYSE:ABC) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance's entry into certain variable pre-paid forward transactions executed in reliance on Rule 144 under the Securities Act of 1933, as amended. AmerisourceBergen intends to repurchase shares from Walgreens Boots Alliance at the per share price equal to the price in the Rule 144 transaction. The concurrent share repurchase will be made under AmerisourceBergen's share repurchase program and the repurchased shares will be held in treasury. About Ameri
Transaction Highlights Walgreens Boots Alliance announces the sale of shares of AmerisourceBergen Corporation pursuant to variable prepaid forward transactions executed in reliance on Rule 144 for current proceeds of approximately $644 million and, depending on the stock price at the time, potentially additional proceeds at maturity, along with a concurrent share repurchase by AmerisourceBergen of approximately $50 million Variable prepaid forward transactions provide liquidity while maintaining ability to participate in potential stock price appreciation Proceeds to Walgreens Boots Alliance will be used primarily for debt paydown and general corporate purposes No changes to ong
Revenue of $63.5 billion for the Second Quarter, a 9.9 Percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $2.13 and Adjusted Diluted EPS of $3.50 Adjusted Diluted EPS Guidance Range Raised to $11.70 to $11.90 for Fiscal 2023 AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2023 second quarter ended March 31, 2023, revenue increased 9.9 percent year-over-year to $63.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to $2.59 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that
New platform-agnostic system aims to improve connectivity across CGT treatment journey to enable enhanced patient and provider experience AmerisourceBergen, a global healthcare company, today announced the launch of its Cell and Gene Therapy (CGT) Integration Hub, a system that can be integrated with biopharma or provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the treatment development and patient journey. The CGT Integration Hub – which is platform-agnostic and powered by AmerisourceBergen's innovative customer relationship management (CRM) system – aims to streamline the path-to-care process, in part, by providing physicians and pat